NCT02552147View on ClinicalTrials.gov

Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

November 17, 2017

Study Completion Date

November 17, 2017

Conditions
Autism Spectrum DisorderAggressionIrritability
Interventions
DRUG

Transdermal nicotine

OTHER

Transdermal placebo

Trial Locations (1)

06511

Yale University, New Haven

All Listed Sponsors
collaborator

Autism Speaks

OTHER

lead

Yale University

OTHER

NCT02552147 - Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism | Biotech Hunter | Biotech Hunter